Welcome to our dedicated page for Qiagen SEC filings (Ticker: QGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The QIAGEN N.V. (QGEN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. QIAGEN files reports on Form 6-K and related documents under the Securities Exchange Act of 1934, covering quarterly financial information, press releases and other material updates for investors in its common shares.
Among the filings available are Form 6-K submissions that furnish QIAGEN’s U.S. GAAP quarterly reports, including periods ended June 30 and September 30, as well as press releases on topics such as unaudited financial results, synthetic share repurchase plans, acquisitions like Parse Biosciences, and leadership changes. These filings often include explanations of how QIAGEN uses adjusted (non-GAAP) metrics and constant currency measures alongside GAAP results, giving readers insight into how management evaluates business performance.
Investors can also review a Form 25 notification of removal from listing and/or registration filed by the New York Stock Exchange in January 2026 for QIAGEN N.V. common shares under Section 12(b) of the Exchange Act. This document confirms that the exchange has taken steps to strike the class of securities from listing and/or withdraw registration on that market, an important reference for understanding QGEN’s trading status on the NYSE.
Stock Titan enhances these filings with AI-powered summaries that explain the key points of lengthy documents such as quarterly reports or complex transaction announcements. Users can quickly see what QIAGEN reports about its Sample to Insight business, including segment performance, capital allocation actions like synthetic share repurchases, and updates on non-GAAP measures, while still having direct access to the original SEC documents.
In addition, this page helps track ongoing disclosure practices, such as corrections to prior balance sheet classifications described in certain Form 6-K filings, and the incorporation by reference of detailed exhibits like U.S. GAAP quarterly reports and major press releases. For anyone analyzing QGEN, this centralized view of SEC filings, combined with AI-generated highlights, offers a practical way to follow the company’s regulatory and financial reporting history.
QIAGEN N.V. filed a Form 6-K as a foreign private issuer to provide its U.S. GAAP quarterly report for the three and six months ended June 30, 2025.
The quarterly report is furnished as Exhibit 99.1 and is incorporated by reference. The filing is signed on behalf of the company by Chief Financial Officer Roland Sackers.
Form 144 filed for QGEN reports a proposed sale of 25,000 common shares on the New York Stock Exchange with an aggregate market value of $1,220,000 and approximately 216,834,000 shares outstanding. The securities to be sold were acquired as restricted stock unit (RSU) awards on multiple dates in 2021 and 2022, with individual lots of 5,918; 5,247; 5,089; 4,253; and 4,493 shares. The filer states no securities were sold in the past three months and affirms they are not aware of undisclosed material adverse information about the issuer. The planned transaction is scheduled for approximately 08/15/2025.
QGEN Form 144 summary: This filing notifies a proposed sale under Rule 144 of 31,423 common shares by an insider brokered through Morgan Stanley Smith Barney on the NYSE, with an aggregate market value of $1,546,256.70 and an approximate sale date of 08/15/2025. The shares were acquired as performance shares on 02/28/2025. The filing also reports sales by the same person during the prior three months totaling 68,577 common shares for gross proceeds of $3,336,720.01 across trades on 08/13–08/14/2025. The filer certifies no undisclosed material adverse information.
Form 144 filed for QIAGEN N.V. (QGEN) reports a proposed sale of 18,577 common shares with an aggregate market value of $910,286, to be sold on 08/14/2025 on the NYSE. The filing lists total outstanding shares of 216,556,000, and shows the securities were acquired as performance shares on 02/21/2023 (9,756 shares), 02/27/2025 (4,736 shares) and 02/28/2025 (4,085 shares). The form also discloses two sales on 08/13/2025 by Roland Sackers totaling 50,000 shares for combined gross proceeds of $2,456,435.00. The filer signs the standard attestation that no material nonpublic information is known.
Qiagen N.V. (QGEN) disclosure shows a proposed sale of 50,000 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $2,456,435.00. With 216,556,000 shares outstanding, the proposed block represents roughly 0.023% of the company. The shares were received as performance shares on 02/21/2023 (15,378 shares) and 02/28/2023 (34,622 shares). The filing reports “Nothing to Report” for sales in the past three months and includes the seller's attestation that they are not aware of undisclosed material adverse information.
Wellington Management entities disclosed beneficial ownership of 26,023,940 shares of Qiagen N.V. (CUSIP N72482206), equal to 11.95% of the outstanding common stock. The filing shows shared voting power of 20,289,753 shares and shared dispositive power of 26,023,940 shares. The reporting persons are multiple Wellington entities, some classified as holding companies and one as an investment adviser, and the securities are owned of record by clients of Wellington investment advisers. The statement affirms the holdings are held in the ordinary course of business and not for the purpose of changing or influencing issuer control.